



UNITED STATES PATENT AND TRADEMARK OFFICE


UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/656,093	09/05/2003	Andrew A. Young	256/152DIV

David R. Marsh  
Attn: IP Docketing Dept.  
ARNOLD & PORTER  
555 12th Street, N.W.  
Washington, DC 20004-1206



CONFIRMATION NO. 8873  
FORMALITIES LETTER



Date Mailed: 03/02/2004

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

*Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

Replies should be mailed to: Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450

Docketed


Due Date

Initial

RESP.


5/2/04

as



gh


*A copy of this notice MUST be returned with the reply.*

A handwritten signature in cursive script, appearing to read "C. L. D.", is written over a horizontal line.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Young et al.

Group Art Unit: Unknown

Confirmation No.: 8873

Serial No: 10/656,093

Filed: September 5, 2003

For: Inotropic and Diuretic Effects of GLP-1 and GLP-1 Agonists

Examiner: Unknown

**Response Under 37 C.F.R. 1.821 and 37 C.F.R. 1.825**

Commissioner for Patents  
Mail Stop Sequence  
P.O. Box 1450  
Alexandria, VA 22313-1450


In response to the Formalities Letter dated March 2, 2004, a copy of which is enclosed, Applicants submit herewith a substitute computer readable form of the sequence listing for the above referenced application as required by 37 C.F.R. 1.825(d). In accordance with 37 C.F.R. 1,821 (f), I hereby state that information recorded in computer readable form (CRF) is identical to the corrected paper sequence listing mailed on February 9, 2004 and includes no new matter.

Applicants believe no fee is due with this response. In the event any fee is deemed necessary, the Commissioner is hereby authorized to charge any such fee that may be required or to credit any overpayment of fees during the pendency of this application to Account No. 01-0535.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "James E. Butler".

James E. Butler, Ph.D., Reg No. 40,931  
Amylin Pharmaceuticals, Inc.  
9360 Towne Centre Drive  
San Diego, CA 92121  
(858) 458-8564



Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Box  
Seq

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	<b>Application Number</b>	10/656,093	
	<b>Filing Date</b>	September 5, 2003	
	<b>First Named Inventor</b>	Young et al.	
	<b>Group Art Unit</b>	Not Yet Assigned	
	<b>Examiner Name</b>	Not Yet Assigned	
<b>Total Number of Pages in This Submission</b>	4	<b>Attorney Docket Number</b>	256/152DIV

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <b>Response to Formalities Letter</b> <b>Substitute CRF of Sequence Listing Disk</b> <b>Copy of Formalities Letter</b> <b>Return Post Card</b>
<b>Remarks</b>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Amylin Pharmaceuticals, Inc. James E. Butler, Ph.D., Reg. No. 40,931
Signature	
Date	April 9, 2004

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Mail Stop Sequence, P.O. Box 1450, Alexandria, VA 22313-1450 on this date: April 9, 2004	
Typed or printed name	Amanda J. Halverson
Signature	
Date	4/9/04 April 9, 2004

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.